Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2012 1
2013 4
2014 3
2015 4
2016 5
2017 3
2018 2
2019 3
2020 7
2021 6
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Sallman DA, et al. Among authors: al ali nh. J Clin Oncol. 2021 May 10;39(14):1584-1594. doi: 10.1200/JCO.20.02341. Epub 2021 Jan 15. J Clin Oncol. 2021. PMID: 33449813 Free PMC article. Clinical Trial.
Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.
Mangaonkar AA, Lasho TL, Ketterling RP, Reichard KK, Gangat N, Al-Kali A, Begna KH, Pardanani A, Al Ali NH, Talati C, Sallman D, Padron E, Patnaik MM, Tefferi A, Komrokji R. Mangaonkar AA, et al. Among authors: al ali nh. Blood Cancer J. 2022 Feb 1;12(2):26. doi: 10.1038/s41408-022-00622-8. Blood Cancer J. 2022. PMID: 35105856 Free PMC article.
SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.
Mangaonkar AA, Lasho TL, Finke C, Ketterling RP, Reichard KK, McCullough K, Gangat N, Al-Kali A, Begna KH, Hogan WH, Litzow MR, Alkhateeb H, Shah M, Pardanani A, Tefferi A, Al Ali NH, Talati C, Sallman D, Padron E, Komrokji R, Patnaik MM. Mangaonkar AA, et al. Among authors: al ali nh. Haematologica. 2022 May 1;107(5):1189-1192. doi: 10.3324/haematol.2021.280463. Haematologica. 2022. PMID: 35142154 Free PMC article. No abstract available.
Autoimmune diseases and myelodysplastic syndromes.
Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Komrokji RS, et al. Among authors: al ali nh. Am J Hematol. 2016 May;91(5):E280-3. doi: 10.1002/ajh.24333. Epub 2016 Apr 4. Am J Hematol. 2016. PMID: 26875020 Free article.
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.
Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Sallman DA, et al. Among authors: al ali nh. Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):e597-e605. doi: 10.1016/j.clml.2020.03.005. Epub 2020 Mar 20. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32303488
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.
Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Kanagal-Shamanna R, et al. Among authors: al ali nh. Blood Cancer J. 2021 Mar 6;11(3):52. doi: 10.1038/s41408-021-00446-y. Blood Cancer J. 2021. PMID: 33677472 Free PMC article. No abstract available.
MYC overexpression is associated with an early disease progression from MDS to AML.
Gajzer D, Logothetis CN, Sallman DA, Calon G, Babu A, Chan O, Vincelette ND, Volpe VO, Al Ali NH, Basra P, Talati C, Kuykendall AT, Mo Q, Padron E, Sweet K, Komrokji RS, Lancet JE, Yun S, Zhang L. Gajzer D, et al. Among authors: al ali nh. Leuk Res. 2021 Dec;111:106733. doi: 10.1016/j.leukres.2021.106733. Epub 2021 Oct 21. Leuk Res. 2021. PMID: 34749168 Free PMC article.
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases.
Fleti F, Chan O, Singh A, Abdelmagid MG, Al-Kali A, Elliott MA, Begna KH, Foran JM, Badar T, Khera N, Al Ali NH, Padron E, Sallman DA, Shah M, Hiwase D, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R, Tefferi A. Fleti F, et al. Among authors: al ali nh. Am J Hematol. 2023 Apr;98(4):E76-E79. doi: 10.1002/ajh.26845. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36655582 Free article. No abstract available.
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al Ali NH, Lancet JE, Cleveland JL, Padron E, List AF. Sallman DA, et al. Among authors: al ali nh. Blood. 2020 Dec 10;136(24):2812-2823. doi: 10.1182/blood.2020006158. Blood. 2020. PMID: 32730593 Free PMC article.
37 results